Atezolizumab (atezo) therapy for upper tract (UT) urothelial carcinoma (UC): Subgroup analysis of the single-arm international SAUL study in pretreated locally advanced/metastatic urinary tract carcinoma.

Cora N. Sternberg,Yohann Loriot,Rosa Tambaro,Consuelo Buttigliero,Franco Morelli,Zsuzsanna Papai,Margitta Retz,Andrea Necchi,Michiel S. van der Heijden,Guy Faust,Andres Felipe Cardona Zorrilla,Nuria Lainez,Stefano Panni,Olatz Etxaniz,Laurence Eliot Miles Krieger,Maria Jose José Mendez Vidal,Maartje Los,Sabine de Ducla,Simon Fear,Axel S. Merseburger

Atezolizumab (atezo) therapy for upper tract (UT) urothelial carcinoma (UC): Subgroup analysis of the single-arm international SAUL study in pretreated locally advanced/metastatic urinary tract carcinoma.

2020

488Background: UTUC is rarer than bladder UC and typically responds poorly to standard chemotherapy. Analysis of 220 biomarker-evaluable atezo-treated patients (pts) in phase II/III trials suggeste...

Keywords:

Urology
Atezolizumab
Urinary system
Subgroup analysis
Pathology
Carcinoma
Medicine
urothelial carcinoma
locally advanced
upper tract
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations